Company / Cost of Revenue
Haemonetics Cost of Revenue History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$617.5M
FY2026
5-year range
$553.6M / $617.5M
FY2022-FY2026
Trend
-
vs FY2025
Sector context
#59 of 113
Health Care
What the data says
At $618M, Haemonetics's cost of revenue ranks #55 of 113 in the Health Care sector. Cost of Revenue has fluctuated over the past 9 years, ranging from $473M in FY2020 to $618M in FY2026.
Based on SEC 10-K filings.
$618M in FY2026 with a 5-year CAGR of +4.8%.
Remained stable around $618M over the past 3 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +0.0%
- 5-Year CAGR
- +4.8%
- 10-Year CAGR
- -
Sector benchmark
#55 of 113 in Health CareTop 48% of 113This company $617.5M Sector average $11.3B
▼
-94.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.8%, indicating consistent growth.
- Ranks #59 out of 113 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2020.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | $617.5M | - |
| FY2025 | - | - |
| FY2024 | $611.9M | -0.9% |
| FY2023 | $617.5M | +11.6% |
| FY2022 | $553.6M | +13.5% |
| FY2021 | $487.7M | +3.2% |
| FY2020 | $472.6M | -6.2% |
| FY2019 | $504.0M | -8.4% |
| FY2018 | $550.0M | +11.8% |
| FY2017 | $492.0M | -3.1% |
As of FY2026 · SEC 10-K · Updated Jun 30, 2026